Pharvaris says Phase 3 RAPIDe-3 trial shows oral deucrictibant cuts median HAE symptom relief time to 1.28 hours

• Pharvaris highlighted clinical data on oral bradykinin B2 antagonist deucrictibant at EAACI 2026, with results already presented during June 12-15.
• Phase 3 RAPIDe-3 findings supported rapid symptom improvement with limited need for additional dosing or rescue treatment, with a clean tolerability profile.
• A prespecified “end of progression” analysis indicated earlier control of attack worsening versus placebo, reinforcing potential differentiation for on-demand use.
• Long-term Phase 2 extension results supported durable prevention of HAE attacks, improved disease control, better quality of life, no meaningful safety signals.
• An integrated cardiovascular review across roughly 570 treated participants showed no signal for clinically meaningful cardiac risk, supporting broader development in HAE.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150650PRIMZONEFULLFEED9746817) on June 15, 2026, and is solely responsible for the information contained therein.